NCT07259317Phase 2Recruiting

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-09Estimated

Enrollment · participants80Estimated

Source updated2026-09-25Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-17 · 3 fields changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Progression-Free Survival (PFS)

+ Updated value

measure: Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1); measure: Number of Patients with 1 or More Adverse Events (AEs) Leading to Study Drug Discontinuations or Dose Modifications (Part 1); measure: Progression-Free Survival (PFS) (Part 2)

The saved outcome text may be shortened. Check the source for full wording.

Enrollment · participant count

Recorded edit

− Previous value

count: 60; type: ESTIMATED

+ Updated value

count: 80; type: ESTIMATED

Primary completion date

Recorded edit

− Previous value

2027-07

+ Updated value

2027-09

Check registry source

Posted 2026-01-29 · 1 field changed

Recruitment status

Recorded edit

− Previous value

Not yet recruiting

+ Updated value

Recruiting

Check registry source

Study details

Conditions studied

Adenocarcinoma; Carcinoma, Pancreatic Ductal

Treatments or interventions studied

RelacorilantDrugAlso known as CORT125134
Nab-paclitaxelDrug
GemcitabineDrug

Primary outcomes · main study measures

Read the study measures

measure: Percent of Patients who Experience Dose Limiting Toxicity (DLT) (Part 1); description: The percentage of patients with a DLT is used to estimate maximum tolerated dose (MTD), the most intense dose/schedule among those evaluated at which \<33% of patients experience DLT.; timeFrame: Up to 28 days after the first dose of study treatment; measure: Number of Patients with 1 or More Adverse Events (AEs) Leading to Study Drug Discontinuations or Dose Modifications (Part 1); timeFrame: Time of first dose up to 30 days after last dose; measure: Progression-Free Survival (PFS) (Part 2); description: To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever comes first.; timeFrame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history